RPG Life Sciences Limited · RPGLIFE
Every RPG Life Sciences Limited result whose ten-session window has closed, judged against the last read made before it. Open a result for the full account: the read, the sessions after, the reported figures, and every morning's read that led up to it. The company's own page →
24results judged
2read right
3read wrong
1flat / no call
18unread
50%beat the market
+0.2%avg vs market, 10d
6.7%avg move, T+1
How the reads on it fared
| Read | Judged | Right | Wrong | Flat | Hit rate | Avg vs mkt | |
|---|---|---|---|---|---|---|---|
| strong | 2 | 0 | 2 | 0 | 0% | -9.2% | |
| favourable | 4 | 2 | 1 | 1 | 67% | +4.5% | |
| unread | 18 | 0 | 0 | 0 | — | +0.3% |
A company that is often read strong and often proves it is one the model understands; one that is read strong and keeps lagging is where the model is wrong about a name, and this table is where that shows first.
Reading the rows
- T+1
- the share's move on the first session after the result, from the close before it
- T+10
- the move over ten sessions, same base
- vs market
- T+10 less NIFTY 50's move over the same ten sessions — the number every read is judged on
- Run-up
- the share's move in the thirty sessions before the result
- Result
- reported profit growth against the company's own last four quarters: good, in line, bad
Each result
24 judged · newest first · open one| Result | Read | Outcome | T+1 | T+10 | vs market | Run-up | Result | Why | |
|---|---|---|---|---|---|---|---|---|---|
| 28 Jul Q1FY27 | strong | wrong | -3.8% | -9.6% | -11.4% | +26% | no figures |
|
› |
| 29 Apr Q4FY26 | favourable | right | +19.0% | +12.9% | +15.1% | +7% | no figures |
|
› |
| 27 Jan Q3FY26 | favourable | wrong | -5.7% | -3.1% | -6.2% | -9% | no figures |
|
› |
| 17 Oct Q2FY26 | favourable | right | +5.9% | +8.1% | +8.5% | -4% | no figures |
|
› |
| 25 Jul Q1FY26 | strong | wrong | -9.3% | -7.9% | -6.9% | +6% | no figures |
|
› |
| 28 Apr Q4FY25 | favourable | neutral | -1.2% | +2.0% | +0.6% | +2% | no figures |
|
› |
| 24 Jan Q3FY25 | — | unread | +7.1% | +15.0% | +13.8% | -9% | no figures |
|
› |
| 7 Nov Q2FY25 | — | unread | -11.6% | -24.4% | -24.5% | +19% | no figures |
|
› |
| 19 Jul Q1FY25 | — | unread | +5.8% | +5.2% | +7.2% | +24% | no figures |
|
› |
| 30 Apr Q4FY24 | — | unread | -4.8% | -3.6% | -2.7% | +11% | no figures |
|
› |
| 1 Feb Q3FY24 | — | unread | +3.5% | +2.1% | +0.5% | +19% | no figures |
|
› |
| 19 Oct Q2FY24 | — | unread | +3.6% | +5.9% | +8.2% | +15% | no figures |
|
› |
| 28 Jul Q1FY24 | — | unread | +2.4% | +7.5% | +8.5% | +12% | no figures |
|
› |
| 28 Apr Q4FY23 | — | unread | -8.5% | -6.9% | -8.1% | +17% | no figures |
|
› |
| 2 Feb Q3FY23 | — | unread | +0.9% | +10.3% | +8.0% | -7% | no figures |
|
› |
| 18 Oct Q2FY23 | — | unread | +5.8% | +10.7% | +6.3% | +4% | no figures |
|
› |
| 2 Aug Q1FY23 | — | unread | +7.4% | +15.7% | +13.3% | +21% | no figures |
|
› |
| 29 Apr Q4FY22 | — | unread | -12.8% | -15.9% | -10.9% | +14% | no figures |
|
› |
| 25 Jan Q3FY22 | — | unread | -4.6% | -8.2% | -10.1% | +4% | no figures |
|
› |
| 29 Oct Q2FY22 | — | unread | +12.4% | +4.1% | +2.3% | -7% | no figures |
|
› |
| 28 Jul Q1FY22 | — | unread | +5.1% | +12.3% | +8.2% | +4% | no figures |
|
› |
| 30 Apr Q4FY21 | — | unread | -7.3% | -9.3% | -12.6% | +24% | no figures |
|
› |
| 25 Jan Q3FY21 | — | unread | -2.3% | -5.0% | -11.1% | +14% | no figures |
|
› |
| 31 Jul Q1FY21 | — | unread | +9.0% | +11.6% | +10.0% | +22% | no figures |
|
› |